US Pharma MarketingThe post What happens when protocol data finally flows appeared first on Clinical Trials Arena.
What happens when protocol data finally flows
Rob DiCicco, vice president of portfolio management, and Bill Illis, workstream leader, digital data flow at TransCelerate BioPharma, highlight the advantages of digital protocols for clinical trials. Rob DiCicco, vice president of portfolio management, and Bill Illis, workstream leader, digital data flow at TransCelerate BioPharma, highlight the advantages of digital protocols for clinical trials. According to data from Tufts CSDD, approximately 75% of clinical studies involve at least one substantial protocol amendment. Credit: Khan Vector Co / Shutterstock.com Rob DiCicco, vice president of portfolio management, and Bill Illis, workstream leader, digital data flow at TransCelerate BioPharma, highlight the advantages of…
Rob DiCicco, vice president of portfolio management, and Bill Illis, workstream leader, digital data flow at TransCelerate BioPharma, highlight the advantages of digital protocols for clinical trials.
Source: Clinical Trials Arena